Built from weaker models, sales multiples or analyst targets, so treat it as a rough guide.
Not used by alerts or posts.
Valued as a loss-making company: Sales comps and Analyst consensus.
ACCE opinionOPKO Health Inc. Common Stock (OPK)
Fair value
Not available
ACCE price target
$1.40
Rating
Not rated
Horizon
12 months
ACCE price target published on 13 Oct 2026, 00:00 CEST.
Price used: $1.63 at the close on 23 Oct 2026, 22:00 CEST.
Models: Analyst consensus and Sales comps.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
ACCE score
42
out of 100
Analysts
67% buy
6 covering
1-year return
+7.2%
Dividend yield
0.00%
OPKO Health Inc. Common Stock in four questions
Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
Overview
ACCE thesis
OPKO Health runs a diagnostics business, anchored by its BioReference Laboratories unit, which performs clinical lab testing, alongside Pharma and Telecare operations including the Rayaldee vitamin D product. The company is not a clean pure play, and that is part of the difficulty: a 19.5% gross margin and a -15.3% operating margin leave little evidence yet that the mix is becoming more profitable. Revenue growth of 4.3% is modest for a business still burning money, and an ROE of -5.9% confirms the earnings base is negative. The forward P/E of 53.8 asks investors to pay for a recovery that the current margins do not yet show. Our score of 37/100 and absence from any index suggest this is a turnaround story that needs proof of operating leverage before it merits a deeper look.
⚠ Investor warnings · 4 flagsAI-assisted·How I use AI
high
Free cash flow deeply negative
Free cash flow is -$190.8M against a $1.1B market cap, with operating margin at -15.3% and net margin at -12.4%. The business is consuming cash faster than it generates it.
high
Earnings and revenue declining
Earnings are down 12.6% year over year and revenue fell 16.4% quarter over quarter. Five-year revenue CAGR is -15.8%, so the decline is structural rather than a single weak quarter.
moderate
Shares trade above ACCE target
At $1.53 the stock sits 16.4% above the ACCE price target of $1.40. The score is 37/100, with quality at 31 and value at 25.
moderate
Elevated short interest
Short interest stands at 8.6% of float, alongside 50.5% insider ownership. Thin public float can amplify price moves in either direction.
AI research notes
AI-assisted·How I use AIWritten Oct 18, 2026 · figures from 2026-06-30 · prices to Oct 23, 2026
Why it could do well
Analysts are broadly positive, with 4 of 6 rating the stock Buy or Strong Buy.
The latest quarter beat expectations, with earnings per share of -0.01 against -0.08 expected.
Revenue grew 4.3% over the past year, a sign the top line is moving up again.
Why it could disappoint
Free cash flow over the last twelve months was negative at -$191M, so the business is burning cash.
Net margin of -12.4% and return on equity of -5.9% show the company is not yet earning a profit on its capital.
The diluted share count rose 8.2% last year, diluting existing shareholders' stake in the company.
Each chip shows the exact figure and where it comes from. A claim without a source is not published.
Next results
Nov 4, 2026
We update the fair value about 2 days after the results, once the new figures are filed.Add to calendarGoogle
Walk me through this stock
Plain-English pros, cons, and what to watch. Pro feature.
PRO
Ask ACCE
Valuation
INVESTOR
Where OPK's valuation models land
Price
$1.63
Model fair valueConfidence: low
about $3.61
Model
Fair value
Upside
Analyst consensus
Sales comps
Create a free account: 5 full stock pages a month, no card.
See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.
Quality
INVESTOR
Quality and conviction INVESTOR FEATURE
The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.
+A plain reason under every score
+Conviction breakdown and growth / value / quality / momentum scores